KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Equity Income (2020 - 2025)

Historic Equity Income for Inovio Pharmaceuticals (INO) over the last 6 years, with Q3 2025 value amounting to $205259.0.

  • Inovio Pharmaceuticals' Equity Income fell 8457.64% to $205259.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 6321.15%. This contributed to the annual value of $2.1 million for FY2024, which is 6440.68% down from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Equity Income stood at $205259.0 for Q3 2025, which was down 8457.64% from $759289.0 recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Equity Income registered a high of $3.2 million during Q1 2023, and its lowest value of -$4.8 million during Q1 2022.
  • Over the past 5 years, Inovio Pharmaceuticals' median Equity Income value was $140234.0 (recorded in 2025), while the average stood at -$105111.8.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Equity Income tumbled by 303055.32% in 2022 and then surged by 371566.19% in 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Equity Income (Quarter) stood at -$2.1 million in 2021, then soared by 235.93% to $2.8 million in 2022, then decreased by 29.22% to $2.0 million in 2023, then crashed by 85.38% to $289132.0 in 2024, then decreased by 29.01% to $205259.0 in 2025.
  • Its Equity Income stands at $205259.0 for Q3 2025, versus $759289.0 for Q2 2025 and $140234.0 for Q1 2025.